tradingkey.logo

Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025

ReutersMay 27, 2025 12:51 PM

- Theriva Biologics Inc TOVX.A:

  • THERIVA™ BIOLOGICS ANNOUNCES PRESENTATION OF DATA FROM VCN-01 RETINOBLASTOMA PHASE 1 CLINICAL TRIAL AT ASCO 2025 AND INVESTIGATOR MEETING TO REVIEW TOPLINE DATA FROM THE VIRAGE PHASE 2B TRIAL OF VCN-01 IN METASTATIC PANCREATIC CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI